STOCK TITAN

XORTX Announces Participation at Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

CALGARY, Alberta, Nov. 03, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that Dr. Allen Davidoff, President and CEO, is scheduled to participate in the following upcoming investor conferences:

Sidotti & Company LLC - November Micro-Cap Virtual Conference
Registration: Sidoti & Co November 9-10 2022 Micro-Cap Virtual Investor Conference Registration

A.G.P.’s Virtual Biotech Conference
Registration: Alliance Global Partners Nov 30th-Dec 1st 2022 Virtual Biotech Investor Conference Registration

Singular Research’s Best of the Uncovereds
Registration: Singular Research's Best of the Uncovereds Conference Dec. 8th 2022 San Francisco Registration

About XORTX Therapeutics Inc.

XORTX is a pharmaceutical company with two clinically advanced products in development: 1) our lead program in XRx-008 for ADPKD; and 2) our secondary program in XRx-101 for acute kidney and other acute organ injury associated with Coronavirus / COVID-19 infection. In addition, XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy. XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, we are dedicated to developing medications to improve the quality of life and future health of patients. Additional information on XORTX is available at www.xortx.com.

For further information, please contact:

Allen Davidoff, CEO Nick Rigopulos, Director of Communications
adavidoff@xortx.com or +1 403 455 7727 nick@alpineequityadv.com or +1 617 901 0785
   
Media Inquiries, David Melamed, Ph.D.  
david.melamed@russopartnersllc.com or +1 212 845 4225  
   

The TSX Venture Exchange and Nasdaq have neither approved nor disapproved the contents of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

Forward Looking Statements

This press release may contain express or implied forward-looking statements pursuant to Canadian and U.S. Federal securities laws. These forward-looking statements and their implications are based on the current reasonable expectations of the management of XORTX only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in such forward-looking statements. Except as otherwise required by law, XORTX undertakes no obligation to publicly release any revisions or updates to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting XORTX is contained in the Company’s most recently filed Annual Information Form and the Management Discussion and Analysis for its most recent financial reporting period filed on the Company’s SEDAR profile (www.sedar.com) and under the heading “Risk Factors” in XORTX’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (“SEC”) available on the SEC's website, www.sec.gov.

 


XORTX Therapeutics Inc

NASDAQ:XRTX

XRTX Rankings

XRTX Latest News

XRTX Stock Data

Support Activities for Nonmetallic Minerals (except Fuels) Mining
Mining, Quarrying, and Oil and Gas Extraction
Link
Canada
Calgary

About XRTX

xortx therapeutics inc., a bio-pharmaceutical company, focuses on the development and commercialization of therapies to treat progressive kidney diseases worldwide. it has two lead programs, including treatments for progressive kidney disease due to diabetes, diabetic nephropathy and polycystic kidney disease. the company focuses on developing therapies for health consequences that includes pre-diabetes, diabetes, and cardiovascular disease. in addition, it develops uric acid lowering agents to treat diabetic nephropathy, hypertension, insulin resistance, metabolic syndrome, and diabetes; and xanthine oxidase inhibitors. the company has a strategic alliance with teijin pharma limited to develop tmx-049, a xanthine oxidoreductase; and a partnership with the icahn school of medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with covid-19. xortx therapeutics inc. is headquartered in calgary, canada.